Brind.

Fresenius Kabi joins ARPA-H program to stabilize biologic medicines

1 report, 1 independent Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The Advanced Research Projects Agency for Health (ARPA-H) awarded Draper up to $7.3 million for Phase 1 of its BioStabilization Systems (BoSS) program. BoSS aims to develop new methods for producing, storing, and transporting cell-based biologic medicines at room temperature. Fresenius Kabi is listed as a performer on the Reversible Ambient Temperature team for the program.

From prnewswire.com

Why it matters

Some supportBrind's analysis of the reports

Biologic treatments are complex medical products that are extremely fragile and require expensive, complex ultra-cold storage, which limits their availability. The BoSS program seeks to overcome this temperature barrier by pursuing new technologies for storage and transport. Fresenius Kabi's participation in this funded program relates to the development of new methods for biologic supply chains.

From prnewswire.com

Who's involved

  • Fresenius KabiPerformer on the Reversible Ambient Temperature team for the BoSS program
  • BOSSProgram funded by ARPA-H to develop room temperature storage for biologic medicines

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Fresenius KabiSpeculative

    As a performer on the funded BoSS team, Fresenius Kabi could benefit from program validation and funding.

  • BOSSSpeculative

    The BoSS program might see increased investment in developing technologies that reduce the cost and complexity of the cold chain.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped